398 related articles for article (PubMed ID: 31768675)
1. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
[TBL] [Abstract][Full Text] [Related]
2. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ishida T; Kimura H; Ozaki S; Kubo K; Sunami K; Takezako N; Fujita H; Hayashi T; Kiguchi T; Ohashi K; Yamamoto S; Takamatsu H; Kosugi H; Ohta K; Sakai R; Handa H; Kondo S; Abe Y; Omoto E; Mitani K; Morita S; Murakami H; Shimizu K
Ann Hematol; 2020 May; 99(5):1063-1072. PubMed ID: 32248251
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
5. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
6. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
[TBL] [Abstract][Full Text] [Related]
8. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T
Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118
[TBL] [Abstract][Full Text] [Related]
9. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
Fujisaki T; Ishikawa T; Takamatsu H; Suzuki K; Min CK; Lee JH; Wang J; Carson R; Crist W; Qi M; Nagafuji K
Ann Hematol; 2019 Dec; 98(12):2805-2814. PubMed ID: 31620815
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Larocca A; Mina R; Offidani M; Liberati AM; Ledda A; Patriarca F; Evangelista A; Spada S; Benevolo G; Oddolo D; Innao V; Cangiolosi C; Bernardini A; Musto P; Amico V; Fraticelli V; Paris L; Giuliani N; Falcone AP; Zambello R; De Paoli L; Romano A; Palumbo A; Montefusco V; Hájek R; Boccadoro M; Bringhen S
Haematologica; 2020 Apr; 105(4):1074-1080. PubMed ID: 31248973
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F
Am J Hematol; 2017 Mar; 92(3):244-250. PubMed ID: 28006855
[TBL] [Abstract][Full Text] [Related]
13. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W; Bang SM; Huang H; Kim K; Li W; An G; Lee JJ; Cai Z; Jin J; Wang Y; Lin TL; Chim CS; Qi M; Wang J; Lu X; Song Y; Jia B; Yang X; Liu W; Zhou T; Yin L; Li Y; Zhang R; Hou J; Wang J
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):446-455.e4. PubMed ID: 37024420
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.
Zhou Q; Xu F; Wen J; Yue J; Zhang Y; Su J; Liu Y
Clin Exp Med; 2023 Sep; 23(5):1573-1580. PubMed ID: 36094683
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
18. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
[TBL] [Abstract][Full Text] [Related]
19. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Lee JH; Moreau P; Niesvizky R; Dimopoulos M; Hajek R; Pour L; Jurczyszyn A; Qiu L; Klippel Z; Zahlten-Kumeli A; Osman M; Paiva B; San-Miguel J
Blood; 2019 May; 133(18):1953-1963. PubMed ID: 30819926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
